Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gilles Berdeaux

Showing results (1-10 of 60) with videos related to

Pageof 6
Sort By:
BMC Ophthalmology|July 17, 2008
Modelling lifetime cost consequences of ReSTOR in cataract surgery in four European countriesAntoine Lafuma, Gilles Berdeaux
Journal of Cataract and Refractive Surgery|October 12, 2004
Adverse clinical consequences of neodymium:YAG laser treatment of posterior capsule opacificationChristian Billotte, Gilles Berdeaux
Clinical Therapeutics|October 9, 2007
Use of a Bayesian network to predict the nighttime intraocular pressure peak from daytime measurementsJean-Philippe Nordmann, Gilles Berdeaux
Investigative Ophthalmology & Visual Science|January 2, 2007
Public health impact of neovascular age-related macular degeneration treatments extrapolated from visual acuityFrancesco Bandello, Antoine Lafuma, Gilles Berdeaux
Journal of Medical Economics|May 20, 2009
Costs and persistence of brimonidine versus brinzolamide in everyday glaucoma care: an analysis conducted on the UK General Practitioner Research DatabaseAntoine Lafuma, Carolini Laurendeau, Gilles Berdeaux
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|January 8, 2011
Metric properties of the MacDQoL, individualized macular-disease-specific quality of life instrument, and newly identified subscales in French, German, Italian, and American populationsGilles Berdeaux, Mounir Mesbah, Clare Bradley
Journal of Glaucoma|July 1, 2004
Medical predictive factors of glaucoma treatment costsPhilippe Denis, Antoine Lafuma, Gilles Berdeaux
Clinical Drug Investigation|May 23, 2007
Medical outcomes of glaucoma therapy from a nationwide representative surveyPhilippe Denis, Antoine Lafuma, Gilles Berdeaux
Acta Ophthalmologica|August 13, 2011
Glaucoma costs in Denmark in treatment naive patientsJens Olsen, Gilles Berdeaux, Jesper Skov
Clinical Ophthalmology (Auckland, N.Z.)|August 12, 2009
Costs and persistence of alpha-2 adrenergic agonists versus carbonic anhydrase inhibitors, both associated with prostaglandin analogues, for glaucoma as recorded by The United Kingdom General Practitioner Research DatabasePhilippe Denis, Antoine Lafuma, Gilles Berdeaux
Pageof 6

Showing results (1-10 of 60) with videos related to

Sort By:
Pageof 6
BMC Ophthalmology|July 17, 2008
Modelling lifetime cost consequences of ReSTOR in cataract surgery in four European countriesAntoine Lafuma, Gilles Berdeaux
Journal of Cataract and Refractive Surgery|October 12, 2004
Adverse clinical consequences of neodymium:YAG laser treatment of posterior capsule opacificationChristian Billotte, Gilles Berdeaux
Clinical Therapeutics|October 9, 2007
Use of a Bayesian network to predict the nighttime intraocular pressure peak from daytime measurementsJean-Philippe Nordmann, Gilles Berdeaux
Investigative Ophthalmology & Visual Science|January 2, 2007
Public health impact of neovascular age-related macular degeneration treatments extrapolated from visual acuityFrancesco Bandello, Antoine Lafuma, Gilles Berdeaux
Journal of Medical Economics|May 20, 2009
Costs and persistence of brimonidine versus brinzolamide in everyday glaucoma care: an analysis conducted on the UK General Practitioner Research DatabaseAntoine Lafuma, Carolini Laurendeau, Gilles Berdeaux
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|January 8, 2011
Metric properties of the MacDQoL, individualized macular-disease-specific quality of life instrument, and newly identified subscales in French, German, Italian, and American populationsGilles Berdeaux, Mounir Mesbah, Clare Bradley
Journal of Glaucoma|July 1, 2004
Medical predictive factors of glaucoma treatment costsPhilippe Denis, Antoine Lafuma, Gilles Berdeaux
Clinical Drug Investigation|May 23, 2007
Medical outcomes of glaucoma therapy from a nationwide representative surveyPhilippe Denis, Antoine Lafuma, Gilles Berdeaux
Acta Ophthalmologica|August 13, 2011
Glaucoma costs in Denmark in treatment naive patientsJens Olsen, Gilles Berdeaux, Jesper Skov
Clinical Ophthalmology (Auckland, N.Z.)|August 12, 2009
Costs and persistence of alpha-2 adrenergic agonists versus carbonic anhydrase inhibitors, both associated with prostaglandin analogues, for glaucoma as recorded by The United Kingdom General Practitioner Research DatabasePhilippe Denis, Antoine Lafuma, Gilles Berdeaux
Pageof 6